Drugs / RTx-015
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06460844 | Aug 2024 → Oct 2030 expected | choroideremia, retinitis pigmentosa | Ray Therapeutics, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RTx-015 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06460844 ↗ |
| Route | Intravitreal | “a single, uniocular intravitreal injection of an investigational optogenetic gene therapy, RTx-015” NCT06460844 ↗ |